Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Autoimmune Disorders

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 231 articles:
HTML format
Text format



Single Articles


    October 2019
  1. PINAL-FERNANDEZ I, Mecoli CA, Casal-Dominguez M, Pak K, et al
    More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies.
    Neurology. 2019 Oct 8. pii: WNL.0000000000008443.
    PubMed     Text format     Abstract available


  2. TUR C, Kalincik T, Oh J, Sormani MP, et al
    Head-to-head drug comparisons in multiple sclerosis: Urgent action needed.
    Neurology. 2019 Oct 7. pii: WNL.0000000000008319.
    PubMed     Text format     Abstract available


    September 2019
  3. PFUHL C, Grittner U, Giess RM, Scheel M, et al
    Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis.
    Neurology. 2019 Sep 9. pii: WNL.0000000000008237.
    PubMed     Text format     Abstract available


  4. EIJLERS AJC, Dekker I, Steenwijk MD, Meijer KA, et al
    Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis.
    Neurology. 2019 Sep 4. pii: WNL.0000000000008198.
    PubMed     Text format     Abstract available


  5. BARKHOF F, Kappos L, Wolinsky JS, Li DKB, et al
    Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
    Neurology. 2019 Sep 4. pii: WNL.0000000000008189.
    PubMed     Text format     Abstract available


    August 2019

  6. Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG.
    Neurology. 2019 Aug 29. pii: WNL.0000000000008232.
    PubMed     Text format    


  7. FAREZ MF, Correale J, Armstrong MJ, Rae-Grant A, et al
    Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019 Aug 28. pii: WNL.0000000000008157.
    PubMed     Text format     Abstract available


  8. MADIGAN NN, Liewluck T, Milone M, Naddaf E, et al
    Necrotizing autoimmune myopathy with tubular aggregates.
    Neurology. 2019;93:313-314.
    PubMed     Text format    


  9. HONORAT JA, Lopez-Chiriboga AS, Kryzer TJ, Komorowski L, et al
    Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG.
    Neurology. 2019 Aug 1. pii: WNL.0000000000008061.
    PubMed     Text format     Abstract available


    July 2019
  10. HAPFELMEIER A, Gasperi C, Donnachie E, Hemmer B, et al
    A large case-control study on vaccination as risk factor for multiple sclerosis.
    Neurology. 2019 Jul 30. pii: WNL.0000000000008012.
    PubMed     Text format     Abstract available


  11. ALGAEED M
    Author response: Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
    Neurology. 2019;93:184.
    PubMed     Text format    


  12. ROBBINS NM, Mozaffar T, Mammen AL, Liewluck T, et al
    Reader response: Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
    Neurology. 2019;93:183-184.
    PubMed     Text format    


  13. GANESH A, Galetta S
    Editors' note: Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
    Neurology. 2019;93:182-183.
    PubMed     Text format    


  14. MATEEN FJ
    Multiple sclerosis in resource-limited settings: Research opportunities in an unequal world.
    Neurology. 2019;93:176-180.
    PubMed     Text format     Abstract available


  15. DE GIGLIO L, De Luca F, Gurreri F, Ferrante I, et al
    Effect of dalfampridine on information processing speed impairment in multiple sclerosis.
    Neurology. 2019 Jul 22. pii: WNL.0000000000007970.
    PubMed     Text format     Abstract available


  16. TITULAER MJ, Irani SR, Lassmann H
    PDE10A antibodies in autoimmune encephalitis: A possible marker of cancer immunotherapy?
    Neurology. 2019 Jul 17. pii: WNL.0000000000007965.
    PubMed     Text format    


  17. ZEKERIDOU A, Kryzer T, Guo Y, Hassan A, et al
    Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity.
    Neurology. 2019 Jul 17. pii: WNL.0000000000007971.
    PubMed     Text format     Abstract available


  18. LAPLAUD DA, Casey R, Barbin L, Debouverie M, et al
    Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.
    Neurology. 2019 Jul 12. pii: WNL.0000000000007938.
    PubMed     Text format     Abstract available


  19. HERSH CM, Marrie RA
    Harnessing real-world data to inform treatment decisions in multiple sclerosis.
    Neurology. 2019 Jul 12. pii: WNL.0000000000007934.
    PubMed     Text format    


    June 2019
  20. SECHI E, Shosha E, Williams JP, Pittock SJ, et al
    Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology.
    Neurology. 2019 Jun 24. pii: WNL.0000000000007828.
    PubMed     Text format     Abstract available


  21. VERBOON C, Doets AY, Galassi G, Davidson A, et al
    Current treatment practice of Guillain-Barre syndrome.
    Neurology. 2019 Jun 7. pii: WNL.0000000000007719.
    PubMed     Text format     Abstract available


  22. GESSANI A, Cavallieri F, Budriesi C, Zucchi E, et al
    Pearls & Oy-sters: Paroxysmal dysarthria-ataxia syndrome: Acoustic analysis in a case of antiphospholipid syndrome.
    Neurology. 2019;92:e2727-e2731.
    PubMed     Text format    


    May 2019
  23. HOWARD JF JR, Bril V, Burns TM, Mantegazza R, et al
    Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
    Neurology. 2019 May 22. pii: WNL.0000000000007600.
    PubMed     Text format     Abstract available


  24. GUIDON AC, Juel VC
    Efgartigimod: A novel antibody depletion therapy in myasthenia gravis.
    Neurology. 2019 May 22. pii: WNL.0000000000007605.
    PubMed     Text format    


  25. MCKAY KA, Hillert J, Manouchehrinia A
    Long-term disability progression ofpediatric-onset multiple sclerosis.
    Neurology. 2019 May 15. pii: WNL.0000000000007647.
    PubMed     Text format     Abstract available


  26. NA S, Lee ES, Kim YD
    Teaching NeuroImages: Pterygoid myositis mimicking giant cell arteritis.
    Neurology. 2019;92:e2297.
    PubMed     Text format    


  27. CALABRESE M, Gasperini C, Tortorella C, Schiavi G, et al
    "Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study.
    Neurology. 2019 May 1. pii: WNL.0000000000007573.
    PubMed     Text format     Abstract available


  28. BROWNLEE WJ
    Differential diagnosis of multiple sclerosis: The better explanations in clinical practice.
    Neurology. 2019 May 1. pii: WNL.0000000000007566.
    PubMed     Text format    


    April 2019
  29. MAILLART E, Mochel F, Acquaviva C, Maisonobe T, et al
    Severe transient myopathy in a progressive multiple sclerosis patient with high-dose biotin.
    Neurology. 2019 Apr 26. pii: WNL.0000000000007576.
    PubMed     Text format    


  30. VILLOSLADA P, Green AJ, Galetta S
    Personalizing medical care for MS patients: Monitoring brainstem damage by infrared oculography.
    Neurology. 2019 Apr 19. pii: WNL.0000000000007493.
    PubMed     Text format    


  31. NIJ BIJVANK JA, van Rijn LJ, Balk LJ, Tan HS, et al
    Diagnosing and quantifying a common deficit in multiple sclerosis: Internuclear ophthalmoplegia.
    Neurology. 2019 Apr 19. pii: WNL.0000000000007499.
    PubMed     Text format     Abstract available


  32. BRITTON JW, Dalmau J
    Recognizing autoimmune encephalitis as a cause of seizures: Treating cause and not effect.
    Neurology. 2019 Apr 12. pii: WNL.0000000000007444.
    PubMed     Text format    


  33. CORTESE M, Chitnis T, Ascherio A, Munger KL, et al
    Total intake of different minerals and the risk of multiple sclerosis.
    Neurology. 2019 Apr 3. pii: WNL.0000000000006800.
    PubMed     Text format     Abstract available


    March 2019
  34. CONWAY DS
    What is the impact of socioeconomic status on multiple sclerosis?
    Neurology. 2019;92:e1536-e1539.
    PubMed     Text format    


  35. GORIS A, Dubois B
    Leveraging human genetics to inform intervention strategies for multiple sclerosis.
    Neurology. 2019 Mar 20. pii: WNL.0000000000007298.
    PubMed     Text format    


  36. THOMSON A, Horne R, Chung C, Marta M, et al
    Visibility and representation of women in multiple sclerosis research.
    Neurology. 2019 Mar 20. pii: WNL.0000000000007276.
    PubMed     Text format     Abstract available


  37. HARROUD A, Morris JA, Forgetta V, Mitchell R, et al
    Effect of age at puberty on risk of multiple sclerosis: A mendelian randomization study.
    Neurology. 2019 Mar 20. pii: WNL.0000000000007325.
    PubMed     Text format     Abstract available


  38. KALINCIK T
    Effectiveness of oral multiple sclerosis therapies in clinical context.
    Neurology. 2019 Mar 15. pii: WNL.0000000000007300.
    PubMed     Text format    


  39. DE MEO E, Meani A, Moiola L, Ghezzi A, et al
    Dynamic gray matter volume changes in pediatric multiple sclerosis: A 3.5-year MRI study.
    Neurology. 2019 Mar 13. pii: WNL.0000000000007267.
    PubMed     Text format     Abstract available


  40. FOX RJ, Cosenza C, Cripps L, Ford P, et al
    A survey of risk tolerance to multiple sclerosis therapies.
    Neurology. 2019 Mar 13. pii: WNL.0000000000007245.
    PubMed     Text format     Abstract available


  41. YEH EA, Eshaghi A
    Evolution of regional brain atrophy in children with multiple sclerosis: Gray matters.
    Neurology. 2019 Mar 13. pii: WNL.0000000000007254.
    PubMed     Text format    


  42. BAR-OR A, Grove RA, Tolson JM, Derosier FJ, et al
    Author response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2019;92:543.
    PubMed     Text format    


  43. KEARNEY H
    Reader response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2019;92:542-543.
    PubMed     Text format    


  44. LEWIS A, Galetta S
    Editors' note: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2019;92:542.
    PubMed     Text format    


  45. ZULUAGA MI, Otero-Romero S, Rovira A, Perez-Hoyos S, et al
    Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis.
    Neurology. 2019 Mar 1. pii: WNL.0000000000007178.
    PubMed     Text format     Abstract available


  46. CASAL-DOMINGUEZ M, Pinal-Fernandez I, Corse AM, Paik J, et al
    Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies.
    Neurology. 2019 Mar 1. pii: WNL.0000000000007188.
    PubMed     Text format     Abstract available


    February 2019
  47. HARDING KE, Wardle M, Carruthers R, Robertson N, et al
    Socioeconomic status and disability progression in multiple sclerosis: A multinational study.
    Neurology. 2019 Feb 22. pii: WNL.0000000000007190.
    PubMed     Text format     Abstract available


  48. BERGER T, Stuve O
    Neurofilament light chain: An important step toward a disease biomarker in multiple sclerosis.
    Neurology. 2019 Feb 8. pii: WNL.0000000000007022.
    PubMed     Text format    


    January 2019
  49. COHEN J, Sotoca J, Gandhi S, Yeshokumar AK, et al
    Autoimmune encephalitis: A costly condition.
    Neurology. 2019 Jan 23. pii: WNL.0000000000006990.
    PubMed     Text format     Abstract available


  50. BERGER JR, Cree BA, Greenberg B, Hemmer B, et al
    Author response: Progressive multifocal leukoencephalopathy after fingolimod treatment.
    Neurology. 2019;92:151.
    PubMed     Text format    


  51. LALIVE PH, Roth S, Du Pasquier R
    Reader response: Progressive multifocal leukoencephalopathy after fingolimod treatment.
    Neurology. 2019;92:151.
    PubMed     Text format    


  52. RUEGG S, Yeh EA, Honnorat J
    Forecasting outcomes in anti-NMDAR encephalitis: Clearer prognostic markers needed.
    Neurology. 2019;92:119-120.
    PubMed     Text format    


  53. BALU R, McCracken L, Lancaster E, Graus F, et al
    A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis.
    Neurology. 2019;92:e244-e252.
    PubMed     Text format     Abstract available


  54. ZETTERBERG H, Svenningsson A
    Serum neurofilament light and prediction of multiple sclerosis in clinically isolated syndrome.
    Neurology. 2019 Jan 11. pii: WNL.0000000000006906.
    PubMed     Text format    


  55. HONCE JM, Nair KV, Sillau S, Valdez B, et al
    Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis.
    Neurology. 2019 Jan 11. pii: WNL.0000000000006916.
    PubMed     Text format     Abstract available


  56. COHEN BA
    Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis.
    Neurology. 2019 Jan 11. pii: WNL.0000000000006924.
    PubMed     Text format    



  57. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;92:112.
    PubMed     Text format    


  58. RAE-GRANT A
    Author response: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;92:110-111.
    PubMed     Text format    


  59. SALTONSTALL L
    Reader response: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;92:109-110.
    PubMed     Text format    


  60. LEWIS A, Galetta S
    Editors' note: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019;92:109.
    PubMed     Text format    


    December 2018
  61. PAPPOLLA A, Midaglia L, Boix Rodriguez CP, Puig AA, et al
    Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis.
    Neurology. 2018 Dec 26. pii: WNL.0000000000006801.
    PubMed     Text format    


  62. GASPERINI C, Prosperini L, Tintore M, Sormani MP, et al
    Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge.
    Neurology. 2018 Dec 26. pii: WNL.0000000000006810.
    PubMed     Text format     Abstract available


    November 2018
  63. MARRIE RA, Butzkueven H, Ascherio A
    Obesity and brain volume loss in multiple sclerosis.
    Neurology. 2018 Nov 14. pii: WNL.0000000000006638.
    PubMed     Text format    


  64. MAHLER C, Unterrainer M, Muth C, Egensperger R, et al
    Imaging microglial activation in tacrolimus-associated CNS vasculitis with translocator protein PET.
    Neurology. 2018;91:936-937.
    PubMed     Text format    


  65. RUCK T, Pfeuffer S, Schulte-Mecklenbeck A, Gross CC, et al
    Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells.
    Neurology. 2018 Nov 7. pii: WNL.0000000000006648.
    PubMed     Text format     Abstract available


    October 2018
  66. BROWNLEE WJ
    Misdiagnosis of multiple sclerosis: If you have a hammer, everything looks like a nail?
    Neurology. 2018 Oct 31. pii: WNL.0000000000006584.
    PubMed     Text format    


  67. SOLOMON AJ, Naismith RT, Cross AH
    Misdiagnosis of multiple sclerosis: Impact of the 2017 McDonald criteria on clinical practice.
    Neurology. 2018 Oct 31. pii: WNL.0000000000006583.
    PubMed     Text format     Abstract available


  68. PORTACCIO E, Amato MP
    Author response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018;91:851.
    PubMed     Text format    


  69. SOTGIU S, Eusebi A, Begliuomini C, Guerini FR, et al
    Reader response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018;91:850.
    PubMed     Text format    


  70. PROSCHMANN U, Akgun K, Ziemssen T
    Reader response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018;91:849-850.
    PubMed     Text format    


  71. LEWIS A, Galetta S
    Editors' note: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018;91:849.
    PubMed     Text format    


  72. KRYSKO KM, Graves J, Rensel M, Weinstock-Guttman B, et al
    Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US.
    Neurology. 2018 Oct 17. pii: WNL.0000000000006471.
    PubMed     Text format     Abstract available


  73. BASAL E, Zalewski N, Kryzer TJ, Hinson SR, et al
    Paraneoplastic neuronal intermediate filament autoimmunity.
    Neurology. 2018 Oct 3. pii: WNL.0000000000006435.
    PubMed     Text format     Abstract available


  74. ALGAEED M, Mukharesh L, Heinzelmann M, Kaminski HJ, et al
    Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
    Neurology. 2018;91:e1365-e1367.
    PubMed     Text format    


    September 2018
  75. CAVALLA P, Gilmore W
    Pregnancy in multiple sclerosis: Data from an administrative claims database.
    Neurology. 2018 Sep 28. pii: WNL.0000000000006371.
    PubMed     Text format    


  76. BAHEERATHAN A, McNamara C, Kalam S, Rane N, et al
    The utility of FDG-PET imaging in distinguishing PML-IRIS from PML in a patient treated with natalizumab.
    Neurology. 2018;91:572-573.
    PubMed     Text format    



  77. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2018;91:538.
    PubMed     Text format    


    August 2018
  78. MIDAGLIA L, Gratacos M, Caronna E, Raguer N, et al
    Myasthenia gravis following alemtuzumab therapy for multiple sclerosis.
    Neurology. 2018 Aug 24. pii: WNL.0000000000006251.
    PubMed     Text format    


  79. RUDANT J, Dupont A, Mikaeloff Y, Bolgert F, et al
    Surgery and risk of Guillain-Barre syndrome: A French nationwide epidemiologic study.
    Neurology. 2018 Aug 24. pii: WNL.0000000000006246.
    PubMed     Text format     Abstract available


  80. BROWNLEE WJ, Miszkiel KA, Tur C, Barkhof F, et al
    Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis.
    Neurology. 2018 Aug 17. pii: WNL.0000000000006207.
    PubMed     Text format     Abstract available


    July 2018
  81. BEDARF JR, Nelles M, Reimann J, Paus S, et al
    Teaching Video NeuroImages: Propriospinal myoclonus as a sequela of Guillain-Barre syndrome.
    Neurology. 2018;91:e297-e299.
    PubMed     Text format    


  82. MARQUES-MATOS C, Melo C, Sampaio M, Rodrigues E, et al
    Child Neurology: Treatable bilateral striatal lesions related to anti-dopamine 2 receptor autoimmunity.
    Neurology. 2018;91:98-101.
    PubMed     Text format    


    June 2018
  83. TSAGKAS C, Magon S, Gaetano L, Pezold S, et al
    Spinal cord volume loss: A marker of disease progression in multiple sclerosis.
    Neurology. 2018 Jun 27. pii: WNL.0000000000005853.
    PubMed     Text format     Abstract available


  84. PRADOS F, Barkhof F
    Spinal cord atrophy rates: Ready for prime time in multiple sclerosis clinical trials?
    Neurology. 2018 Jun 27. pii: WNL.0000000000005873.
    PubMed     Text format    


  85. HAGENS MHJ, Burggraaff J, Kilsdonk ID, de Vos ML, et al
    Three-Tesla MRI does not improve the diagnosis of multiple sclerosis: A multicenter study.
    Neurology. 2018 Jun 20. pii: WNL.0000000000005825.
    PubMed     Text format     Abstract available


  86. VITT JR, Kreple C, Mahmood N, Dickerson E, et al
    Autoimmune pancerebellitis associated with pembrolizumab therapy.
    Neurology. 2018 Jun 6. pii: WNL.0000000000005781.
    PubMed     Text format    


  87. PROSPERINI L, Lucchini M, Haggiag S, Bellantonio P, et al
    Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.
    Neurology. 2018 Jun 6. pii: WNL.0000000000005772.
    PubMed     Text format     Abstract available


    May 2018
  88. LEHMANN HC, Compston A, Hartung HP
    150th anniversary of clinical description of multiple sclerosis: Leopold Ordenstein's legacy.
    Neurology. 2018;90:1011-1016.
    PubMed     Text format     Abstract available


  89. KIM DD, Ho C, King R, Morrow SA, et al
    Pearls & Oy-sters: An unusual neuropsychiatric manifestation of systemic lupus erythematosus.
    Neurology. 2018;90:e1929-e1932.
    PubMed     Text format    


  90. LIEWLUCK T
    Author response: Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
    Neurology. 2018;90:990.
    PubMed     Text format    


  91. BUDHRAM A
    Reader response: Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
    Neurology. 2018;90:990.
    PubMed     Text format    


  92. KARAM C, Galetta S
    Editors' note: Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
    Neurology. 2018;90:989.
    PubMed     Text format    


  93. SCALFARI A, Romualdi C, Nicholas RS, Mattoscio M, et al
    The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis.
    Neurology. 2018 May 16. pii: WNL.0000000000005685.
    PubMed     Text format     Abstract available


  94. SHANKLIN A, Cox A, Ahmed HMA, Lieberman A, et al
    Clinical Reasoning: A 77-year-old man presenting with episodic expressive aphasia.
    Neurology. 2018;90:e1822-e1826.
    PubMed     Text format    


  95. DE LORENZO R, Pinal-Fernandez I, Huang W, Albayda J, et al
    Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies.
    Neurology. 2018 May 4. pii: WNL.0000000000005638.
    PubMed     Text format     Abstract available


  96. FRANKLIN GM, McDonnell G
    Free health care, great data, and new clues on multiple sclerosis.
    Neurology. 2018 May 2. pii: WNL.0000000000005593.
    PubMed     Text format    


  97. LOPEZ CHIRIBOGA AS, Matsumoto J, Sorenson E, Klein CJ, et al
    Teaching Video NeuroImages: Acquired focal neuromyotonia in LGI-1 autoimmunity.
    Neurology. 2018;90:e1636-e1637.
    PubMed     Text format    


    April 2018
  98. GERARDI C, Bertele' V, Rossi S, Garattini S, et al
    Preapproval and postapproval evidence on drugs for multiple sclerosis.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005561.
    PubMed     Text format     Abstract available


  99. BAR-OR A, Grove RA, Austin DJ, Tolson JM, et al
    Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005516.
    PubMed     Text format     Abstract available


  100. COBO-CALVO A, Ruiz A, Maillart E, Audoin B, et al
    Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.
    Neurology. 2018 Apr 25. pii: WNL.0000000000005560.
    PubMed     Text format     Abstract available


  101. RAE-GRANT A, Day GS, Marrie RA, Rabinstein A, et al
    Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2018;90:789-800.
    PubMed     Text format     Abstract available


  102. RAE-GRANT A, Day GS, Marrie RA, Rabinstein A, et al
    Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2018;90:777-788.
    PubMed     Text format     Abstract available


  103. HEWETT K, Sanders DB, Grove RA, Broderick CL, et al
    Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis.
    Neurology. 2018;90:e1425-e1434.
    PubMed     Text format     Abstract available


  104. PEDROSO JL, Dutra LA, Espay AJ, Hoftberger R, et al
    Video NeuroImages: Head titubation in anti-mGluR1 autoantibody-associated cerebellitis.
    Neurology. 2018;90:746-747.
    PubMed     Text format    


  105. CORREALE J, Ysrraelit MC, Benarroch EE
    Metabolic coupling of axons and glial cells: Implications for multiple sclerosis progression.
    Neurology. 2018;90:737-744.
    PubMed     Text format    


    March 2018
  106. FERRARO D, Camera V, Vitetta F, Zennaro M, et al
    Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.
    Neurology. 2018 Mar 30. pii: WNL.0000000000005417.
    PubMed     Text format    


  107. SAARELA M, Senthil K, Jones J, Tienari PJ, et al
    Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab.
    Neurology. 2018 Mar 30. pii: WNL.0000000000005420.
    PubMed     Text format    


  108. FRATTINI E, Monfrini E, Bitetto G, Ferrari B, et al
    Clinical Reasoning: A 75-year-old man with parkinsonism, mood depression, and weight loss.
    Neurology. 2018;90:572-575.
    PubMed     Text format    


  109. ROTSTEIN DL, Chen H, Wilton AS, Kwong JC, et al
    Temporal trends in multiple sclerosis prevalence and incidence in a large population.
    Neurology. 2018 Mar 16. pii: WNL.0000000000005331.
    PubMed     Text format     Abstract available


  110. GAETANO L, Haring DA, Radue EW, Mueller-Lenke N, et al
    Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.
    Neurology. 2018 Mar 14. pii: WNL.0000000000005292.
    PubMed     Text format     Abstract available


  111. SCHOONHEIM MM, Ciccarelli O
    The value of including thalamic atrophy as a clinical trial endpoint in multiple sclerosis.
    Neurology. 2018 Mar 14. pii: WNL.0000000000005279.
    PubMed     Text format    


  112. MCKAY KA, Tremlett H, Fisk JD, Zhang T, et al
    Psychiatric comorbidity is associated with disability progression in multiple sclerosis.
    Neurology. 2018 Mar 9. pii: WNL.0000000000005302.
    PubMed     Text format     Abstract available


  113. MILLER AE, Calabresi PA
    Central vein sign in multiple sclerosis: Ready for front and center?
    Neurology. 2018 Mar 7. pii: WNL.0000000000005241.
    PubMed     Text format    


  114. TREMLETT H, Zhu F, Ascherio A, Munger KL, et al
    Sun exposure over the life course and associations with multiple sclerosis.
    Neurology. 2018 Mar 7. pii: WNL.0000000000005257.
    PubMed     Text format     Abstract available


    February 2018
  115. PATIL A, Shree R, Naheed D, Goyal MK, et al
    Pearls & Oy-sters: Paraneoplastic cerebral vasculitis: Rare cause of spontaneous convexity subarachnoid hemorrhage.
    Neurology. 2018;90:e815-e817.
    PubMed     Text format    


  116. CHATAWAY J, Martin K, Barrell K, Sharrack B, et al
    Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis.
    Neurology. 2018 Feb 21. pii: WNL.0000000000005118.
    PubMed     Text format     Abstract available


  117. BATEMAN EM, Schleicher WE, Smith EJ, Sweet DR, et al
    Journal Club: MRI reveals acute inflammation in cortical lesions during early MS.
    Neurology. 2018;90:e724-e726.
    PubMed     Text format     Abstract available


  118. PORTACCIO E, Annovazzi P, Ghezzi A, Zaffaroni M, et al
    Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
    Neurology. 2018 Feb 7. pii: WNL.0000000000005067.
    PubMed     Text format     Abstract available


  119. PORTACCIO E, Moiola L, Martinelli V, Annovazzi P, et al
    Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.
    Neurology. 2018 Feb 7. pii: WNL.0000000000005068.
    PubMed     Text format     Abstract available


  120. ALROUGHANI R, Alowayesh MS, Ahmed SF, Behbehani R, et al
    Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era.
    Neurology. 2018 Feb 2. pii: WNL.0000000000005065.
    PubMed     Text format     Abstract available


  121. SALVARANI C, Brown RD Jr, Christianson TJH, Huston J 3rd, et al
    Primary central nervous system vasculitis associated with lymphoma.
    Neurology. 2018 Feb 2. pii: WNL.0000000000005062.
    PubMed     Text format     Abstract available


    January 2018
  122. BENNETT S, Leavitt VM
    An intervention to improve balance in persons with multiple sclerosis.
    Neurology. 2018 Jan 31. pii: WNL.0000000000005038.
    PubMed     Text format    


  123. HEBERT JR, Corboy JR, Vollmer T, Forster JE, et al
    Efficacy of Balance and Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS).
    Neurology. 2018 Jan 31. pii: WNL.0000000000005013.
    PubMed     Text format     Abstract available


  124. WEHRUM T, Beume LA, Stich O, Mader I, et al
    Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis.
    Neurology. 2018 Jan 19. pii: WNL.0000000000004950.
    PubMed     Text format     Abstract available


  125. PETERSEN ER, Oturai AB, Koch-Henriksen N, Magyari M, et al
    Smoking affects the interferon beta treatment response in multiple sclerosis.
    Neurology. 2018 Jan 17. pii: WNL.0000000000004949.
    PubMed     Text format     Abstract available


  126. SUMOWSKI JF, Benedict R, Enzinger C, Filippi M, et al
    Cognition in multiple sclerosis: State of the field and priorities for the future.
    Neurology. 2018 Jan 17. pii: WNL.0000000000004977.
    PubMed     Text format     Abstract available


  127. ALLENBACH Y, Arouche-Delaperche L, Preusse C, Radbruch H, et al
    Necrosis in anti-SRP(+) and anti-HMGCR(+)myopathies: Role of autoantibodies and complement.
    Neurology. 2018 Jan 12. pii: WNL.0000000000004923.
    PubMed     Text format     Abstract available


  128. ZHANG T, Tremlett H, Zhu F, Kingwell E, et al
    Effects of physical comorbidities on disability progression in multiple sclerosis.
    Neurology. 2018 Jan 3. pii: WNL.0000000000004885.
    PubMed     Text format     Abstract available


    December 2017
  129. PISA M, Guerrieri S, Di Maggio G, Medaglini S, et al
    No evidence of disease activity is associated with reduced rate of axonal retinal atrophy in MS.
    Neurology. 2017;89:2469-2475.
    PubMed     Text format     Abstract available


  130. DUBEY D, Lennon VA, Gadoth A, Pittock SJ, et al
    Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases.
    Neurology. 2017 Dec 8. pii: WNL.0000000000004803.
    PubMed     Text format     Abstract available


  131. LOREFICE L, Fenu G, Gerevini S, Frau J, et al
    PML in a person with multiple sclerosis: Is teriflunomide the felon?
    Neurology. 2017 Dec 6. pii: WNL.0000000000004804.
    PubMed     Text format    


  132. FITZGERALD KC, Tyry T, Salter A, Cofield SS, et al
    Diet quality is associated with disability and symptom severity in multiple sclerosis.
    Neurology. 2017 Dec 6. pii: WNL.0000000000004768.
    PubMed     Text format     Abstract available


  133. SUMOWSKI JF, McDonnell GV, Bourdette D
    Diet in multiple sclerosis: Science takes a seat at the table.
    Neurology. 2017 Dec 6. pii: WNL.0000000000004775.
    PubMed     Text format    


    November 2017
  134. BURNOR E, Yang L, Zhou H, Patterson KR, et al
    Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies.
    Neurology. 2017 Nov 29. pii: WNL.0000000000004773.
    PubMed     Text format     Abstract available


  135. KLAWITER EC, Bove R, Elsone L, Alvarez E, et al
    High risk of postpartum relapses in neuromyelitis optica spectrum disorder.
    Neurology. 2017;89:2238-2244.
    PubMed     Text format     Abstract available


  136. LARONI A, Signori A, Maniscalco GT, Lanzillo R, et al
    Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study.
    Neurology. 2017;89:2222-2229.
    PubMed     Text format     Abstract available


  137. KARCESKI S
    How comorbid conditions affect the choice of treatment in multiple sclerosis.
    Neurology. 2017;89:e265-e267.
    PubMed     Text format    


  138. DHAWAN PS, Dyck PJB, Tracy JA, Naddaf E, et al
    Systemic vasculitis with dermatomyositis, hearing loss, neuropathy, and multiorgan dysfunction.
    Neurology. 2017;89:2119-2120.
    PubMed     Text format    


  139. KOWALEC K, McKay KA, Patten SB, Fisk JD, et al
    Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study.
    Neurology. 2017 Nov 8. pii: 10.1212/WNL.0000000000004716.
    PubMed     Text format     Abstract available


  140. BURMAN J, Zelano J
    Epilepsy in multiple sclerosis: A nationwide population-based register study.
    Neurology. 2017 Nov 8. pii: 10.1212/WNL.0000000000004740.
    PubMed     Text format     Abstract available


  141. HOUZEN H, Kondo K, Niino M, Horiuchi K, et al
    Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan.
    Neurology. 2017;89:1995-2001.
    PubMed     Text format     Abstract available


  142. ARRAMBIDE G, Tintore M, Auger C, Rio J, et al
    Lesion topographies in multiple sclerosis diagnosis: A reappraisal.
    Neurology. 2017 Nov 3. pii: 10.1212/WNL.0000000000004715.
    PubMed     Text format     Abstract available


  143. BARNETT C, Bril V, Kapral M, Kulkarni AV, et al
    Myasthenia Gravis Impairment Index: Responsiveness, meaningful change, and relative efficiency.
    Neurology. 2017 Nov 3. pii: 10.1212/WNL.0000000000004676.
    PubMed     Text format     Abstract available


    October 2017
  144. NOVAKOVA L, Zetterberg H, Sundstrom P, Axelsson M, et al
    Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.
    Neurology. 2017 Oct 27. pii: 10.1212/WNL.0000000000004683.
    PubMed     Text format     Abstract available


  145. CHIANG S, Kesari NK, Bradshaw A, Chen W, et al
    Pearls & Oy-sters: CNS lymphoma in a patient with relapsing-remitting multiple sclerosis treated with interferon.
    Neurology. 2017;89:e210-e213.
    PubMed     Text format    


  146. MATHIS S, Magy L, Le Masson G, Vallat JM, et al
    Did Jules Dejerine describe AMAN at the end of the 19th century?
    Neurology. 2017;89:1749-1753.
    PubMed     Text format     Abstract available


  147. KARGIOTIS O, Safouris A, Petrou VN, Magoufis G, et al
    Teaching NeuroImages: Giant cell arteritis presenting with acute ischemic strokes due to diffuse intracranial stenoses.
    Neurology. 2017;89:e190-e191.
    PubMed     Text format    


  148. TSIVGOULIS G, Papadimitropoulos GN, Katsanos AH, Zompola C, et al
    Teaching NeuroImages: Interferon-induced psoriasis flare in a multiple sclerosis case remits with dimethyl fumarate.
    Neurology. 2017;89:e188-e189.
    PubMed     Text format    


  149. MUNGER KL, Hongell K, Aivo J, Soilu-Hanninen M, et al
    25-Hydroxyvitamin D deficiency and risk of MS among women in the Finnish Maternity Cohort.
    Neurology. 2017;89:1578-1583.
    PubMed     Text format     Abstract available


    September 2017
  150. LIEWLUCK T
    Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
    Neurology. 2017 Sep 27. pii: 10.1212/WNL.0000000000004610.
    PubMed     Text format    


  151. KARCESKI S
    Multiple sclerosis, inflammation in the brain, and mood.
    Neurology. 2017;89:e169-e171.
    PubMed     Text format    


  152. MARRIE RA, Salter A, Tyry T, Cutter GR, et al
    Author response: High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017;89:1429-1430.
    PubMed     Text format    


  153. SETHI NK
    Letter re: High hypothetical interest in physician-assisted death in multiple sclerosis and Physician-assisted death in chronic neurologic diseases.
    Neurology. 2017;89:1429.
    PubMed     Text format    


  154. MASDEU JC
    Letter re: High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017;89:1428.
    PubMed     Text format    


  155. THORMANN A, Sorensen PS, Koch-Henriksen N, Laursen B, et al
    Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality.
    Neurology. 2017 Sep 20. pii: 10.1212/WNL.0000000000004508.
    PubMed     Text format     Abstract available


  156. PLAVINA T, Muralidharan KK, Kuesters G, Mikol D, et al
    Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
    Neurology. 2017 Sep 15. pii: 10.1212/WNL.0000000000004485.
    PubMed     Text format     Abstract available


  157. MARRIE RA, Beck CA
    Preventing multiple sclerosis: To (take) vitamin D or not to (take) vitamin D?
    Neurology. 2017 Sep 13. pii: 10.1212/WNL.0000000000004506.
    PubMed     Text format    


  158. LOPEZ-CHIRIBOGA AS, Clardy SL
    Emerging Subspecialties in Neurology: Autoimmune neurology.
    Neurology. 2017;89:e129-e133.
    PubMed     Text format    


  159. FILLI L, Zorner B, Killeen T, Linnebank M, et al
    Author response: Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Neurology. 2017;89:1200.
    PubMed     Text format    


  160. DAVIS FA
    Letter re: Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Neurology. 2017;89:1199.
    PubMed     Text format    


  161. COLES AJ, Cohen JA, Fox EJ, Giovannoni G, et al
    Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
    Neurology. 2017;89:1117-1126.
    PubMed     Text format     Abstract available


  162. HAVRDOVA E, Arnold DL, Cohen JA, Hartung HP, et al
    Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.
    Neurology. 2017;89:1107-1116.
    PubMed     Text format     Abstract available


  163. LORSCHEIDER J, Jokubaitis VG, Spelman T, Izquierdo G, et al
    Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.
    Neurology. 2017;89:1050-1059.
    PubMed     Text format     Abstract available


    August 2017
  164. LANGER-GOULD A, Wu J, Lucas R, Smith J, et al
    Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility: A multiethnic study.
    Neurology. 2017 Aug 30. pii: 10.1212/WNL.0000000000004412.
    PubMed     Text format     Abstract available


  165. HENNES EM, Baumann M, Schanda K, Anlar B, et al
    Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome.
    Neurology. 2017;89:900-908.
    PubMed     Text format     Abstract available


  166. ROSSI S, Studer V, Motta C, Polidoro S, et al
    Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004411.
    PubMed     Text format     Abstract available


  167. KOCH-HENRIKSEN N, Lauer K
    Dietary sodium intake: An etiologic dead end in multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004426.
    PubMed     Text format    


  168. CORTESE M, Yuan C, Chitnis T, Ascherio A, et al
    No association between dietary sodium intake and the risk of multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004417.
    PubMed     Text format     Abstract available


  169. WIENDL H, Bourdette D, Ciccarelli O
    Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?
    Neurology. 2017 Aug 23. pii: 10.1212/WNL.0000000000004381.
    PubMed     Text format    


  170. DE MEO E, Moiola L, Ghezzi A, Veggiotti P, et al
    MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients.
    Neurology. 2017 Aug 18. pii: 10.1212/WNL.0000000000004388.
    PubMed     Text format     Abstract available


  171. SUZUKI S, Ishikawa N, Konoeda F, Seki N, et al
    Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
    Neurology. 2017 Aug 18. pii: 10.1212/WNL.0000000000004359.
    PubMed     Text format     Abstract available


  172. BEECHER G, Anderson D, Siddiqi ZA
    Subcutaneous immunoglobulin in myasthenia gravis exacerbation: A prospective, open-label trial.
    Neurology. 2017 Aug 16. pii: 10.1212/WNL.0000000000004365.
    PubMed     Text format     Abstract available



  173. Escalation therapy for multiple sclerosis in Austria: Analysis of gender differences in the nationwide registry.
    Neurology. 2017;89:752.
    PubMed     Text format    


  174. HEHIR MK, Hobson-Webb LD, Benatar M, Barnett C, et al
    Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.
    Neurology. 2017 Aug 11. pii: 10.1212/WNL.0000000000004341.
    PubMed     Text format     Abstract available


    July 2017
  175. NIELSEN NM, Munger KL, Stenager E, Ascherio A, et al
    Author response: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:411.
    PubMed     Text format    


  176. XIA Z, Cheng Q, Li J
    Letter re: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:410-411.
    PubMed     Text format    


  177. ZARGHAMI A
    Letter re: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:410.
    PubMed     Text format    


  178. MARANZANO J, Rudko DA, Nakamura K, Cook S, et al
    MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis.
    Neurology. 2017 Jul 19. pii: 10.1212/WNL.0000000000004227.
    PubMed     Text format     Abstract available


  179. HACOHEN Y, Mankad K, Chong WK, Barkhof F, et al
    Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
    Neurology. 2017;89:269-278.
    PubMed     Text format     Abstract available


  180. LANGER-GOULD A, Smith JB, Hellwig K, Gonzales E, et al
    Breastfeeding, ovulatory years, and risk of multiple sclerosis.
    Neurology. 2017 Jul 12. pii: 10.1212/WNL.0000000000004207.
    PubMed     Text format     Abstract available



  181. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.
    Neurology. 2017;89:215.
    PubMed     Text format    


  182. URUHA A, Suzuki S, Nishino I
    Author update: Sarcoplasmic MxA expression: A valuable marker of dermatomyositis.
    Neurology. 2017;89:215.
    PubMed     Text format    


  183. BURKILL S, Montgomery S, Hajiebrahimi M, Hillert J, et al
    Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012.
    Neurology. 2017 Jul 7. pii: 10.1212/WNL.0000000000004216.
    PubMed     Text format     Abstract available


    June 2017
  184. LEWIS EJH, Perkins BA, Lovblom LE, Bazinet RP, et al
    Effect of omega-3 supplementation on neuropathy in type 1 diabetes: A 12-month pilot trial.
    Neurology. 2017;88:2294-2301.
    PubMed     Text format     Abstract available


  185. DE JONG HJI, Kingwell E, Shirani A, Cohen Tervaert JW, et al
    Evaluating the safety of beta-interferons in MS: A series of nested case-control studies.
    Neurology. 2017;88:2310-2320.
    PubMed     Text format     Abstract available


  186. BRENNA G, Antozzi C, Montomoli C, Baggi F, et al
    A propensity score analysis for comparison of T-3b and VATET in myasthenia gravis.
    Neurology. 2017 Jun 7. pii: 10.1212/WNL.0000000000004082.
    PubMed     Text format     Abstract available


    May 2017
  187. BATISTA S, Alves C, d'Almeida OC, Afonso A, et al
    Disconnection as a mechanism for social cognition impairment in multiple sclerosis.
    Neurology. 2017 May 31. pii: 10.1212/WNL.0000000000004060.
    PubMed     Text format     Abstract available


  188. SOLOMON AJ, Weinshenker BG
    Author response: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2017;88:2067-2068.
    PubMed     Text format    


  189. DALLA COSTA G, Martinelli V, Comi G
    Letter re: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2017;88:2067.
    PubMed     Text format    


  190. ESHAGHI A, Ciccarelli O
    Author response: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2017;88:1875.
    PubMed     Text format    


  191. AVASARALA J
    Letter re: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2017;88:1875.
    PubMed     Text format    


  192. TIMMINGS PL, Siu R, Bukhari W, Todd A, et al
    Author response: Acute Zika infection with concurrent onset of Guillain-BarrE syndrome.
    Neurology. 2017;88:1874-1875.
    PubMed     Text format    


  193. GERARDIN P, Cao-Lormeau VM, Tournebize P, Cerny T, et al
    Letter re: Acute Zika infection with concurrent onset of Guillain-BarrE syndrome.
    Neurology. 2017;88:1874.
    PubMed     Text format    


  194. MEIJER KA, Eijlers AJC, Douw L, Uitdehaag BMJ, et al
    Increased connectivity of hub networks and cognitive impairment in multiple sclerosis.
    Neurology. 2017 May 3. pii: 10.1212/WNL.0000000000003982.
    PubMed     Text format     Abstract available


  195. AUBERT-BROCHE B, Weier K, Longoni G, Fonov VS, et al
    Monophasic demyelination reduces brain growth in children.
    Neurology. 2017;88:1744-1750.
    PubMed     Text format     Abstract available


  196. GAIG C, Graus F, Compta Y, Hogl B, et al
    Clinical manifestations of the anti-IgLON5 disease.
    Neurology. 2017;88:1736-1743.
    PubMed     Text format     Abstract available


    April 2017
  197. SORMANI MP, Muraro PA, Schiavetti I, Signori A, et al
    Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.
    Neurology. 2017 Apr 28. pii: 10.1212/WNL.0000000000003987.
    PubMed     Text format     Abstract available


  198. GIANFRANCESCO MA, Stridh P, Rhead B, Shao X, et al
    Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS.
    Neurology. 2017;88:1623-1629.
    PubMed     Text format     Abstract available


  199. NUNLEY KA, Leckie RL, Orchard TJ, Costacou T, et al
    Physical activity and hippocampal volume in middle-aged patients with type 1 diabetes.
    Neurology. 2017;88:1564-1570.
    PubMed     Text format     Abstract available


  200. MADDISON P, Gozzard P, Grainge MJ, Lang B, et al
    Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome.
    Neurology. 2017;88:1334-1339.
    PubMed     Text format     Abstract available


    March 2017
  201. LANDI D, De Rossi N, Zagaglia S, Scarpazza C, et al
    No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
    Neurology. 2017;88:1144-1152.
    PubMed     Text format     Abstract available


  202. ABSINTA M, Cortese IC, Vuolo L, Nair G, et al
    Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases.
    Neurology. 2017 Mar 10. pii: 10.1212/WNL.0000000000003820.
    PubMed     Text format     Abstract available


    February 2017
  203. NASH RA, Hutton GJ, Racke MK, Popat U, et al
    High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.
    Neurology. 2017;88:842-852.
    PubMed     Text format     Abstract available


  204. KUHLE J, Nourbakhsh B, Grant D, Morant S, et al
    Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
    Neurology. 2017;88:826-831.
    PubMed     Text format     Abstract available


  205. MOWRY EM, McArthur JC
    PML in natalizumab-treated multiple sclerosis: Modeling errors and risk miscalculations.
    Neurology. 2017 Feb 22. pii: 10.1212/WNL.0000000000003749.
    PubMed     Text format    


  206. MOLKO N, Simon O, Guyon D, Biron A, et al
    Zika virus infection and myasthenia gravis: Report of 2 cases.
    Neurology. 2017 Feb 10. pii: 10.1212/WNL.0000000000003697.
    PubMed     Text format    


  207. BARTON J, Hardy TA, Riminton S, Reddel SW, et al
    Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003694.
    PubMed     Text format    


  208. WYNN DP, Donigan JM, Tkach A
    Clinical Reasoning: A 74-year-old woman with bilateral foot pain and a palmar rash.
    Neurology. 2017;88:e44-e50.
    PubMed     Text format    


  209. BODINI B, Calabresi PA
    From neurofilament research to multiple sclerosis clinical practice: Where do we stand?
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003676.
    PubMed     Text format    


  210. BENNETT SE
    Fampridine: Long-term benefits in walking in multiple sclerosis.
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003677.
    PubMed     Text format    


    January 2017
  211. SCHEIBE F, Pruss H, Mengel AM, Kohler S, et al
    Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis.
    Neurology. 2017;88:366-370.
    PubMed     Text format     Abstract available


  212. MAAROUF A, Audoin B, Pariollaud F, Gherib S, et al
    Increased total sodium concentration in gray matter better explains cognition than atrophy in MS.
    Neurology. 2017;88:289-295.
    PubMed     Text format     Abstract available


    December 2016
  213. ROCCA MA, Battaglini M, Benedict RH, De Stefano N, et al
    Brain MRI atrophy quantification in MS: From methods to clinical application.
    Neurology. 2016 Dec 16. pii: 10.1212/WNL.0000000000003542.
    PubMed     Text format     Abstract available


  214. GOEDEE HS, van der Pol WL, van Asseldonk JH, Franssen H, et al
    Diagnostic value of sonography in treatment-naive chronic inflammatory neuropathies.
    Neurology. 2016 Dec 7. pii: 10.1212/WNL.0000000000003483.
    PubMed     Text format     Abstract available


    November 2016
  215. TENSER RB, Truini A, Cruccu G
    A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.
    Neurology. 2016;87:2385-2386.
    PubMed     Text format    


  216. BEADNALL HN, Gill AJ, Riminton S, Barnett MH, et al
    Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.
    Neurology. 2016 Nov 16. pii: 10.1212/WNL.0000000000003434.
    PubMed     Text format    


    October 2016
  217. BOURDETTE D
    Rituximab for treating multiple sclerosis: Off-label but on target.
    Neurology. 2016 Oct 19. pii: 10.1212/WNL.0000000000003345.
    PubMed     Text format    


    September 2016
  218. KANTOR D, Sotirchos ES, Calabresi PA
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2016;87:1424.
    PubMed     Text format    


  219. KELLY DM, Kelleher EM, O'Shea A, Sweeney B, et al
    Teaching Video NeuroImages: Primary writing tremor: Lessons from a patient with multiple sclerosis.
    Neurology. 2016;87:e131.
    PubMed     Text format    


  220. ARNOLD DL, Fisher E, Brinar VV, Cohen JA, et al
    Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS.
    Neurology. 2016 Sep 2. pii: 10.1212/WNL.0000000000003169.
    PubMed     Text format     Abstract available


    July 2016
  221. SIU R, Bukhari W, Todd A, Gunn W, et al
    Acute Zika infection with concurrent onset of Guillain-Barre Syndrome.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003038.
    PubMed     Text format    


  222. BROWNLEE WJ, Swanton JK, Miszkiel KA, Miller DH, et al
    Should the symptomatic region be included in dissemination in space in MRI criteria for MS?
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000002975.
    PubMed     Text format     Abstract available


  223. FERREIRA DA SILVA IR, Frontera JA, Moreira do Nascimento OJ
    News from the battlefront: Zika virus-associated Guillain-BarrE Syndrome in Brazil.
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000003024.
    PubMed     Text format    


    May 2016
  224. KOELMAN DL, Chahin S, Mar SS, Venkatesan A, et al
    Acute disseminated encephalomyelitis in 228 patients: A retrospective, multicenter US study.
    Neurology. 2016;86:2085-93.
    PubMed     Text format     Abstract available


  225. HYUN JW, Jeong IH, Joung A, Kim SH, et al
    Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder.
    Neurology. 2016;86:1772-9.
    PubMed     Text format     Abstract available


  226. SPATOLA M, Du Pasquier R, Schluep M, Regeniter A, et al
    Serum and CSF GQ1b antibodies in isolated ophthalmologic syndromes.
    Neurology. 2016;86:1780-4.
    PubMed     Text format     Abstract available


  227. KASSAVETIS P, Joseph JB, Francois R, Perloff MD, et al
    Zika virus-associated Guillain-Barre syndrome variant in Haiti.
    Neurology. 2016 May 6. pii: 10.1212/WNL.0000000000002759.
    PubMed     Text format    


  228. VAN SONDEREN A, Schreurs MW, de Bruijn MA, Boukhrissi S, et al
    The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies.
    Neurology. 2016;86:1692-9.
    PubMed     Text format     Abstract available


  229. MELINYSHYN AN, Gofton TE, Schulz V
    Supernumerary phantom limbs in ICU patients with acute inflammatory demyelinating polyneuropathy.
    Neurology. 2016;86:1726-8.
    PubMed     Text format     Abstract available


    April 2016
  230. DE LOTT LB, Burke JF, Kerber KA, Skolarus LE, et al
    Medicare Part D payments for neurologist-prescribed drugs.
    Neurology. 2016;86:1491-8.
    PubMed     Text format     Abstract available


    March 2016
  231. HODEL J, Darchis C, Outteryck O, Verclytte S, et al
    Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
    Neurology. 2016 Mar 23. pii: 10.1212/WNL.0000000000002586.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: